Rubella Diagnostic Testing Market

Rubella Diagnostic Testing Market size was valued at USD 5.12 Bn. in 2023 and the total revenue is expected to grow at 4.5% through 2024 to 2030, reaching nearly USD 6.97 Bn. by 2030.

Rubella Diagnostic Testing Market Overview:

Rubella diagnostic testing is a procedure carried out for the detection of antibodies that are developed by the immune system to destroy the rubella viruses. The virus responsible for the rubella infection is positive-stranded RNA Virus as a rubivirus in the matanviridae family. Being a contagious virus, it spreads from one person to another by coughing or sneezing by an infected person.To know about the Research Methodology :- Request Free Sample Report

Rubella Diagnostic Testing Market Dynamics:

Increasing no. of rubella diagnostic testing with government initiatives to control the infection rate and advancement in point-of-care diagnosis is estimated to fuel the growth of the market in the forecast period.

As per WHO in December 2021, 168 out of 195 countries had introduced rubella vaccines and the global coverage was estimated at 69%. Further, the cases were reduced from 670893 reported casts from 102 countries in the year 2000 to 14621 reported cases in 151 countries in 2021. Moreover, CSR rates are higher in WHO African and South-East Asian region due to lower vaccination coverages. This factor is likely to boost the rubella diagnostic testing in Africa as compared to other regions globally.

Moreover, government initiatives towards the end-to-end vaccination by the government by organizing healthcare programs for free of cost vaccination are likely to boost the growth of the market in the forecast period. Further, new products launch by the market players is playing a vital role in the market.

For instance, Abbott Company launched a test kit for rubella virus named as Abbott Rubella-PLUS Test. As a result, this test offers simple and accurate with quick result optimization detection of rubella antibodies.

Rubella Diagnostic Testing Market Segment Analysis:

The Enzyme Immunoassay segment is considered to supplement the growth of the Global Rubella Diagnostic Testing Market

The enzyme immunoassay segment is dominating the Rubella diagnostic testing market with the largest market share of USD 21400 million in 2021 with a CAGR of 6.7% during the forecast period. Enzyme Immunoassay is the standard test for the detection of rubella-specific immunoglobulins M(IgM) in the serum for rapid laboratory diagnosis of rubella. IgM is the most preferred test for the rubella virus with the help of commercial enzyme immunoassay (EIA).

The companies manufacturing the Enzyme Immunoassay system are focusing on product development and mergers and acquisitions to sustain themselves in the market. The major companies are Biohit Oyj, DIA LAB Services Srl, Dynex Technologies, Inc., Fujirebio, Inova Diagnostics, Meril Life Sciences, Tosoh, bioMérieux. Due to these factors, companies are gaining more attention and wider adoption of the diagnostic system. Ans this factor is likely to motivate the market.
In Nov 2021, bioMérieux acquired the majority of the share stake in Suzhou Hybiome Biomedical Engineering Co. Ltd. As a result, to strengthen the company’s presence in China Market.

The Hospital segment is dominating the application segment of the Global Rubella Diagnostic Testing Market:

The hospital segment is dominating the application segment of the global rubella diagnostic testing market with a market share of 34% in 2021 and is estimated to grow at a high pace during the forecast period. The growth of the segment is attributed to the rising no. of hospitals and the implementation of technologies for rapid results. Moreover, healthcare industries are growing at a rapid pace in the market due to government funding and policies. The rising prevalence of infectious diseases is likely to motivate the growth of the market in the coming future. As the growth of the infectious disease is hitting the market and values for 29.3% in 2021. Hence, these factors are likely to motivate the growth of rubella diagnostics in the forecast period.

Rubella Diagnostic Testing Market Regional Insights:

Asia Pacific is gaining a significant market share with the highest CAGR of 12.3% during the forecast period. Moreover, rising population and improving healthcare facilities with easy access are likely to boost the growth of the market. Further, increasing demand for cut healthcare expenses is likely to boost the growth of the market. The dominating countries of Asia Pacific are India, China, and Japan due to the presence of prominent market players in the region. Further, Asia Pacific has registered the fastest growth rate for the rubella diagnostics testing market is likely to grow at the same pace in the future. Besides, lack of awareness in an underdeveloped country, and government initiatives are likely to retain the market growth.

North America is likely to gain significant market share in the Rubella Diagnostic Testing market with 8.7% of the market share in 2021. In addition, mergers, acquisitions, and the launching of new products are likely to boost the growth of the market during the forecast period.

The objective of the report is to present a comprehensive analysis of the Global Rubella Diagnostic Testing Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.

The report also helps in understanding the Global Market dynamics, structure by analyzing the market segments and project the Global Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.

Rubella Diagnostic Testing Market Scope: Inquire before buying

Rubella Diagnostic Testing Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)

Rubella Diagnostic Testing Market Key Player

1. Abbott
2. Bio Rad Laboratories Inc.
3. bioMérieux SA
4. Siemens Healthcare GmbH
5. Thermo Fisher Scientific Inc.
6. Biohit Oyj
7. DIA LAB Services Srl
8. Dynex Technologies, Inc.
9. Fujirebio
10. Inova Diagnostics
11. Meril Life Sciences
12. Tosoh

FAQs:

1. What is the global Rubella Diagnostic Testing market share in 2023?
Ans: Approximately, 5.12 Billion USD.

2. What is the global Rubella Diagnostic Testing market growth?
Ans: The global Rubella Diagnostic Testing market is anticipated to grow with a CAGR of 4.5% in the forecast period and is likely to reach USD 6.97 Billion by the end of 2030.

3. Which Application segment is expected to dominate the global Rubella Diagnostic Testing market during the forecast period?
Ans: The Hospital segment dominated the Rubella Diagnostic Testing market with a Market share of 34 % in 2023.

4. Which region is expected to dominate the global Rubella Diagnostic Testing market during the forecast period?
Ans: Asia pacific dominated the Rubella Diagnostic Testing market with a share of over 12.3% in 2023 owing to rising various drug innovations and diagnostic treatments.

5. Who are the key players in the global Rubella Diagnostic Testing market?
Ans: Key players of the market include Abbott, Bio Rad Laboratories Inc., bioMérieux SA, Siemens Healthcare GmbH, Thermo Fisher Scientific In